Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy (Q35888438)
Jump to navigation
Jump to search
scientific article published on 10 January 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy |
scientific article published on 10 January 2012 |
Statements
1 reference
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy (English)
1 reference
A Pohl
1 reference
A El-Khoueiry
1 reference
D Yang
1 reference
W Zhang
1 reference
G Lurje
1 reference
Y Ning
1 reference
T Winder
1 reference
S Hu-Lieskoven
1 reference
S Iqbal
1 reference
K D Danenberg
1 reference
M Kahn
1 reference
J-L Teo
1 reference
J Shriki
1 reference
J Stebbing
1 reference
H-J Lenz
1 reference
10 January 2012
1 reference
1 reference
173-180
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference